ATE423140T1 - Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften - Google Patents
Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaftenInfo
- Publication number
- ATE423140T1 ATE423140T1 AT06011173T AT06011173T ATE423140T1 AT E423140 T1 ATE423140 T1 AT E423140T1 AT 06011173 T AT06011173 T AT 06011173T AT 06011173 T AT06011173 T AT 06011173T AT E423140 T1 ATE423140 T1 AT E423140T1
- Authority
- AT
- Austria
- Prior art keywords
- regions
- binding properties
- immunoglobulin domains
- molecule different
- determining complementarity
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title abstract 4
- 102000018358 immunoglobulin Human genes 0.000 title abstract 4
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64114405P | 2005-01-05 | 2005-01-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE423140T1 true ATE423140T1 (de) | 2009-03-15 |
Family
ID=36445146
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06703578T ATE425186T1 (de) | 2005-01-05 | 2006-01-05 | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
AT06121439T ATE414718T1 (de) | 2005-01-05 | 2006-01-05 | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
AT08168439T ATE548386T1 (de) | 2005-01-05 | 2006-01-05 | Synthetische immunglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
AT06011173T ATE423140T1 (de) | 2005-01-05 | 2006-01-05 | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06703578T ATE425186T1 (de) | 2005-01-05 | 2006-01-05 | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
AT06121439T ATE414718T1 (de) | 2005-01-05 | 2006-01-05 | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
AT08168439T ATE548386T1 (de) | 2005-01-05 | 2006-01-05 | Synthetische immunglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
Country Status (23)
Country | Link |
---|---|
US (8) | US20090298195A1 (de) |
EP (4) | EP1699826B1 (de) |
JP (3) | JP4937138B2 (de) |
KR (2) | KR101404512B1 (de) |
CN (2) | CN103555733A (de) |
AT (4) | ATE425186T1 (de) |
AU (1) | AU2006204459B2 (de) |
BR (1) | BRPI0606399A8 (de) |
CA (1) | CA2594356C (de) |
CY (3) | CY1108767T1 (de) |
DE (3) | DE602006003695D1 (de) |
DK (4) | DK1699826T3 (de) |
EA (1) | EA018897B1 (de) |
ES (4) | ES2320374T3 (de) |
HR (3) | HRP20090087T3 (de) |
IL (1) | IL184103A (de) |
MX (1) | MX2007008118A (de) |
NZ (1) | NZ555893A (de) |
PL (3) | PL1699826T3 (de) |
PT (4) | PT1699826E (de) |
RS (3) | RS50785B (de) |
SI (3) | SI1699826T1 (de) |
WO (1) | WO2006072620A1 (de) |
Families Citing this family (205)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1797127T3 (en) | 2004-09-24 | 2017-10-02 | Amgen Inc | Modified Fc molecules |
JP4937138B2 (ja) | 2005-01-05 | 2012-05-23 | エフ−シュタール・ビオテヒノロギシェ・フォルシュングス−ウント・エントヴィックルングスゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 相補性決定領域とは異なる分子の領域に設計された結合性を持つ合成免疫グロブリンドメイン |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
AT503889B1 (de) * | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
AT503902B1 (de) * | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
AT503861B1 (de) * | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
TW200831528A (en) | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
EP1975178A1 (de) * | 2007-03-30 | 2008-10-01 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Transzytotischer modularer Antikörper |
WO2008124858A2 (en) * | 2007-04-11 | 2008-10-23 | F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. | Targeted receptor |
AU2008252935B2 (en) | 2007-05-24 | 2013-01-31 | Baxter Healthcare Sa | Antibodies useful for therapy and diagnosis of cancer |
WO2009000006A1 (en) * | 2007-06-26 | 2008-12-31 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. | Display of binding agents |
MX2010003450A (es) | 2007-09-26 | 2010-04-27 | Chugai Pharmaceutical Co Ltd | Region constante de anticuerpo modificada. |
US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
EP2769991B1 (de) | 2008-01-03 | 2018-08-22 | The Scripps Research Institute | Antikörper-targeting mittels modularer erkennungsdomäne |
US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
WO2009099961A2 (en) * | 2008-01-31 | 2009-08-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Engineered antibody constant domain molecules |
AU2014200215B2 (en) * | 2008-01-31 | 2016-09-29 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Engineered antibody constant domain molecules |
EP2113255A1 (de) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Zytotoxisches Immunglobulin |
US20100136584A1 (en) * | 2008-09-22 | 2010-06-03 | Icb International, Inc. | Methods for using antibodies and analogs thereof |
WO2010040105A2 (en) | 2008-10-02 | 2010-04-08 | Trubion Pharmaceuticals, Inc. | Cd86 antagonist multi-target binding proteins |
US8580267B2 (en) | 2008-12-19 | 2013-11-12 | Philogen S.P.A. | Immunocytokines for tumour therapy with chemotherapeutic agents |
CN101609096B (zh) * | 2009-07-21 | 2012-11-07 | 上海师范大学 | 肺癌标志物检测免疫层析试纸的制备方法 |
ES2640981T3 (es) | 2009-08-05 | 2017-11-07 | Philogen S.P.A. | Selección como diana de neovasculatura de médula ósea |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
EP2516467A2 (de) | 2009-12-23 | 2012-10-31 | Emergent Product Development Seattle, LLC | Zusammensetzungen mit tnf-alpha- und il-6-antagonisten und verwendungsverfahren dafür |
EP2519544A1 (de) | 2009-12-29 | 2012-11-07 | Emergent Product Development Seattle, LLC | Polypeptidheterodimere und ihre verwendung |
AU2011215684A1 (en) * | 2010-02-12 | 2012-08-30 | Research Corporation Technologies | Multimeric proteins comprising immunoglobulin constant domains |
EP2407487A1 (de) | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispezifische modulare Antikörper |
US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
DK3029066T3 (da) | 2010-07-29 | 2019-05-20 | Xencor Inc | Antistoffer med modificerede isoelektriske punkter |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
EP2640750A1 (de) | 2010-11-16 | 2013-09-25 | Boehringer Ingelheim International GmbH | Mittel und verfahren zur behandlung von mit bcma-expression korrelierenden erkrankungen |
JP2014508511A (ja) | 2010-12-20 | 2014-04-10 | メドイミューン・リミテッド | 抗il−18抗体およびそれらの使用 |
US9156917B2 (en) | 2011-02-11 | 2015-10-13 | Research Corporation Technologies, Inc. | CH2 domain template molecules derived from rational grafting of donor loops onto CH2 scaffolds |
SG194510A1 (en) | 2011-04-22 | 2013-12-30 | Emergent Product Dev Seattle | Prostate-specific membrane antigen binding proteins and related compositionsand methods |
CN103842383B (zh) | 2011-05-16 | 2017-11-03 | 健能隆医药技术(上海)有限公司 | 多特异性fab融合蛋白及其使用方法 |
ES2704038T3 (es) | 2011-05-24 | 2019-03-13 | Zyngenia Inc | Complejos multiespecíficos multivalentes y monovalentes y sus usos |
CN103827300A (zh) | 2011-06-30 | 2014-05-28 | 中外制药株式会社 | 异源二聚化多肽 |
EP2546268A1 (de) | 2011-07-13 | 2013-01-16 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Internalisierendes Immunglobulin |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
CN104302665B (zh) * | 2011-12-21 | 2019-04-23 | 安姆根有限公司 | 与新生儿Fc受体的结合增强的变体Fc多肽 |
CA2863216C (en) * | 2012-01-09 | 2020-06-02 | Covx Technologies Ireland Limited | Mutant antibodies and conjugation thereof |
CN102585000B (zh) * | 2012-02-22 | 2013-05-29 | 尉军 | 一种肿瘤标志物cd25自身抗体及应用 |
WO2013138643A1 (en) | 2012-03-16 | 2013-09-19 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Soluble engineered monomeric fc |
US9969813B2 (en) | 2012-05-10 | 2018-05-15 | Bioatla, Llc | Multi-specific monoclonal antibodies |
US9585970B2 (en) * | 2012-06-04 | 2017-03-07 | Novartis Ag | Site-specific labeling methods and molecules produced thereby |
WO2013187495A1 (ja) | 2012-06-14 | 2013-12-19 | 中外製薬株式会社 | 改変されたFc領域を含む抗原結合分子 |
TWI717591B (zh) | 2012-08-24 | 2021-02-01 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
EP2906597B1 (de) | 2012-10-15 | 2020-04-08 | Medimmune Limited | Antikörper gegen amyloid beta |
CN104968678B (zh) | 2012-12-05 | 2018-12-11 | 诺华股份有限公司 | 靶向epo的抗体的组合物和方法 |
JP6433297B2 (ja) | 2012-12-27 | 2018-12-05 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
WO2014110601A1 (en) | 2013-01-14 | 2014-07-17 | Xencor, Inc. | Novel heterodimeric proteins |
US9738722B2 (en) | 2013-01-15 | 2017-08-22 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
EP2762496A1 (de) | 2013-02-05 | 2014-08-06 | EngMab AG | Verfahren zur Auswahl von Antikörpern gegen BCMA |
ES2829499T3 (es) | 2013-02-05 | 2021-06-01 | Engmab Sarl | Método para la selección de anticuerpos contra BCMA |
WO2014152832A1 (en) | 2013-03-14 | 2014-09-25 | Immusoft Corporation | Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
BR112015023752B1 (pt) | 2013-03-15 | 2023-11-14 | Zyngenia, Inc. | Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
EP3421495A3 (de) | 2013-03-15 | 2019-05-15 | Xencor, Inc. | Modulation von t-zellen mit bispezifischen antikörpern und fc-fusionen |
KR20210130260A (ko) | 2013-04-02 | 2021-10-29 | 추가이 세이야쿠 가부시키가이샤 | Fc영역 개변체 |
EP2789630A1 (de) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispezifische Antikörper gegen CD3e und ROR1 |
ES2746136T3 (es) | 2013-04-29 | 2020-03-04 | Hoffmann La Roche | Anticuerpos modificados de unión a FcRn humano y procedimientos de uso |
CA2956667A1 (en) | 2013-07-29 | 2015-02-05 | Bluebird Bio, Inc. | Multipartite signaling proteins and uses thereof |
KR101800295B1 (ko) | 2013-09-04 | 2017-12-20 | 엘지디스플레이 주식회사 | 위치감지방법, 위치감지장치, 안테나 장치 및 디스플레이 장치 |
GB201317622D0 (en) * | 2013-10-04 | 2013-11-20 | Star Biotechnology Ltd F | Cancer biomarkers and uses thereof |
NZ758715A (en) | 2013-10-31 | 2023-01-27 | Seattle Children’S Hospital Dba Seattle Children’S Res Institute | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof |
CN105940107B (zh) * | 2013-11-11 | 2021-06-15 | 中外制药株式会社 | 含有改变了抗体可变区的抗原结合分子 |
KR20230007559A (ko) | 2013-12-20 | 2023-01-12 | 프레드 허친슨 캔서 센터 | 태그된 키메라 이펙터 분자 및 그의 리셉터 |
KR20160104636A (ko) | 2014-01-15 | 2016-09-05 | 에프. 호프만-라 로슈 아게 | 단백질 A-결합이 개선된 Fc-영역 변이체 |
CA2943167A1 (en) * | 2014-03-24 | 2015-10-01 | University Of Southampton | Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof |
CR20160506A (es) | 2014-03-28 | 2017-03-10 | Xencor Inc | Anticuerpos biespecíficos que se unen a cd38 y cd3 |
JP2017520575A (ja) | 2014-07-01 | 2017-07-27 | ファイザー・インク | 二重特異的ヘテロ二量体ダイアボディおよびその使用 |
TWI679259B (zh) | 2014-08-11 | 2019-12-11 | 德商漢高智慧財產控股公司 | 光學透明的熱熔黏著劑及其用途 |
AU2015329965A1 (en) | 2014-10-09 | 2017-04-27 | Engmab Sàrl | Bispecific antibodies against CD3epsilon and ROR1 |
JP7125248B2 (ja) | 2014-11-11 | 2022-08-24 | 中外製薬株式会社 | 改変された抗体可変領域を含む抗原結合分子のライブラリ |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
DK3223845T3 (da) | 2014-11-26 | 2021-08-16 | Xencor Inc | Heterodimere antistoffer, der binder cd3 og cd20 |
CA2968878A1 (en) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd38 |
US10982008B2 (en) | 2014-12-05 | 2021-04-20 | Merck Patent Gmbh | Domain-exchanged antibody |
EP3234107B1 (de) | 2014-12-19 | 2022-09-14 | Immusoft Corporation | B-zellen zur in-vivo-verabreichung von therapeutika |
EP3237449A2 (de) | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Trispezifische antikörper |
CN114773470A (zh) | 2015-02-05 | 2022-07-22 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用 |
US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
KR20170117450A (ko) | 2015-02-18 | 2017-10-23 | 엔리벡스 테라퓨틱스 리미티드 | 암 치료를 위한 면역 요법 및 사이토카인 조절 요법의 조합 |
US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
CA3177938A1 (en) | 2015-03-05 | 2016-09-09 | Fred Hutchinson Cancer Center | Immunomodulatory fusion proteins and uses thereof |
TW201642897A (zh) | 2015-04-08 | 2016-12-16 | F 星生物科技有限公司 | Her2結合劑治療 |
US10857181B2 (en) | 2015-04-21 | 2020-12-08 | Enlivex Therapeutics Ltd | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
EP3995142A3 (de) | 2015-04-29 | 2022-08-24 | Fred Hutchinson Cancer Center | Modifizierte hämatopoietische stamm-/vorläuferzellen und non-t effektorzellen sowie verwendungen davon |
EP3288570A4 (de) | 2015-04-29 | 2018-11-21 | Fred Hutchinson Cancer Research Center | Modifizierte stammzellen und verwendungen davon |
KR101997241B1 (ko) | 2015-05-21 | 2019-07-09 | 하푼 테라퓨틱스, 인크. | 삼중특이성 결합 단백질 및 사용 방법 |
US10683369B2 (en) | 2015-08-03 | 2020-06-16 | Engmab Sàrl | Monoclonal antibodies against BCMA |
JP2018525389A (ja) | 2015-08-12 | 2018-09-06 | ノバルティス アーゲー | 眼障害を治療する方法 |
JP7002446B2 (ja) | 2015-09-21 | 2022-03-04 | アプティーボ リサーチ アンド デベロップメント エルエルシー | Cd3結合ポリペプチド |
ES2880682T3 (es) * | 2015-10-05 | 2021-11-25 | Fredax Ab | Anticuerpos anti PSA (5A10) humanizados |
CN108699136B (zh) | 2015-12-07 | 2022-03-18 | Xencor股份有限公司 | 结合cd3和psma的异二聚抗体 |
CA3014885A1 (en) | 2016-02-18 | 2017-08-24 | Enlivex Therapeutics Ltd. | Combination immune therapy and cytokine control therapy for cancer treatment |
US10982136B2 (en) | 2016-02-26 | 2021-04-20 | The Regents Of The University Of California | Ligand-sensitized lanthanide nanocrystals as ultraviolet downconverters |
CN105664157A (zh) * | 2016-03-11 | 2016-06-15 | 江苏亲合力病毒检测工程有限公司 | 一种抗巨细胞病毒人源化抗体药物 |
CN109476756B (zh) | 2016-03-15 | 2022-05-31 | 埃泰美德(香港)有限公司 | 一种多特异性Fab融合蛋白及其用途 |
EP3429620A1 (de) | 2016-03-15 | 2019-01-23 | AstraZeneca AB | Kombination aus einem bac- inhibitor und einem antikörper- oder antigenbindenden fragment zur behandlung einer erkrankung im zusammenhang mit der akkumulation von amyloid beta |
WO2017177137A1 (en) * | 2016-04-07 | 2017-10-12 | Bluebird Bio, Inc. | Chimeric antigen receptor t cell compositions |
CA3020857A1 (en) | 2016-04-14 | 2017-10-19 | Fred Hutchinson Cancer Research Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
JP7042467B2 (ja) | 2016-05-20 | 2022-03-28 | ハープーン セラピューティクス,インク. | 単鎖可変フラグメントcd3結合タンパク質 |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
BR112018073739A2 (pt) | 2016-05-20 | 2019-02-26 | Harpoon Therapeutics, Inc. | proteína de ligação de albumina sérica de domínio único |
WO2017218707A2 (en) | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
JP7085708B2 (ja) | 2016-06-20 | 2022-06-17 | エフ-スター セラピューティクス リミテッド | Lag-3結合要素 |
SI3472207T1 (sl) | 2016-06-20 | 2021-04-30 | F-Star Delta Limited | Vezavne molekule, ki vežejo PD-L1 in LAG-3 |
CN116063545A (zh) | 2016-06-28 | 2023-05-05 | Xencor股份有限公司 | 结合生长抑素受体2的异源二聚抗体 |
EP3484516A4 (de) | 2016-07-14 | 2020-03-18 | Fred Hutchinson Cancer Research Center | Mehrere bispezifische bindungsdomänenkonstrukte mit unterschiedlicher epitopbindung zur behandlung von krebs |
GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
CN116271014A (zh) | 2016-08-05 | 2023-06-23 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
US11235076B2 (en) | 2016-08-29 | 2022-02-01 | Fred Hutchinson Cancer Research Center | Chelating platform for delivery of radionuclides |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
WO2018048812A1 (en) | 2016-09-06 | 2018-03-15 | The Regents Of The University Of California | Formulations of hydroxypyridonate actinide/lanthanide decorporation agents |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
EP3526241A1 (de) | 2016-10-14 | 2019-08-21 | Xencor, Inc. | Il15/il15r-heterodimere fc-fusionsproteine |
CN110167964B (zh) | 2016-11-02 | 2023-12-01 | 百时美施贵宝公司 | 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物 |
KR102275008B1 (ko) | 2016-11-23 | 2021-07-13 | 하푼 테라퓨틱스, 인크. | 전립선 특이 막 항원 결합 단백질 |
MX2019006045A (es) | 2016-11-23 | 2019-11-11 | Harpoon Therapeutics Inc | Proteinas triespecificas dirigidas a psma y metodos de uso. |
WO2018106993A1 (en) * | 2016-12-09 | 2018-06-14 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Tlr9-binding chimeric antigen receptors |
GB201700345D0 (en) | 2017-01-09 | 2017-02-22 | F-Star Beta Ltd | Conditional agonists of immune responses |
ES2949364T3 (es) | 2017-02-17 | 2023-09-28 | Fred Hutchinson Cancer Center | Terapias de combinación para el tratamiento de cánceres y trastornos autoinmunitarios relacionados con BCMA |
CA3053375A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Engineered transferrin receptor binding polypeptides |
EP3589662A4 (de) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | Induzierbares monovalentes antigenbindendes protein |
MX2019010812A (es) | 2017-03-17 | 2019-12-11 | Hutchinson Fred Cancer Res | Proteinas de fusion inmunomoduladoras y sus usos. |
EP3621648A4 (de) | 2017-05-12 | 2021-01-20 | Harpoon Therapeutics, Inc. | Auf trispezifische proteine abzielendes msln und verfahren zur verwendung |
US10543271B2 (en) | 2017-05-12 | 2020-01-28 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
CN111132733A (zh) | 2017-06-30 | 2020-05-08 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白 |
WO2019070577A1 (en) | 2017-10-02 | 2019-04-11 | Denali Therapeutics Inc. | FUSION PROTEINS COMPRISING SUBSTITUTE ENZYM THERAPY ENZYMES |
EP3694871A4 (de) | 2017-10-13 | 2021-11-10 | Harpoon Therapeutics, Inc. | B-zellreifungs-antigenbindende proteine |
US11136403B2 (en) | 2017-10-13 | 2021-10-05 | Harpoon Therapeutics, Inc. | Trispecific proteins and methods of use |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
US11312770B2 (en) | 2017-11-08 | 2022-04-26 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
TW201938194A (zh) | 2017-12-05 | 2019-10-01 | 日商中外製藥股份有限公司 | 包含結合cd3及cd137的改變的抗體可變區之抗原結合分子 |
CN111565737A (zh) | 2017-12-14 | 2020-08-21 | 蓝鸟生物公司 | Daric白细胞介素受体 |
CA3086199A1 (en) | 2017-12-19 | 2019-06-27 | Xencor, Inc. | Engineered il-2 fc fusion proteins |
WO2019121906A1 (en) | 2017-12-19 | 2019-06-27 | F-Star Beta Limited | Specific pd-l1 binding sequences inserted in a ch3 domain |
MX2020009296A (es) | 2018-03-15 | 2020-11-13 | Chugai Pharmaceutical Co Ltd | Anticuerpos anti-virus del dengue que tienen reactividad cruzada con el virus zika y metodos de uso. |
US10982006B2 (en) | 2018-04-04 | 2021-04-20 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
US10633458B2 (en) | 2018-04-10 | 2020-04-28 | Y-Biologics Inc. | Cell engaging binding molecules |
KR20210010862A (ko) | 2018-04-18 | 2021-01-28 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도 |
WO2019204655A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
WO2019222278A1 (en) * | 2018-05-14 | 2019-11-21 | Harpoon Therapeutics, Inc. | Dual binding moiety |
EP3794038A4 (de) * | 2018-05-14 | 2022-02-16 | Harpoon Therapeutics, Inc. | Bindungseinheit zur bedingten aktivierung von immunoglobulinmolekülen |
US20210221914A1 (en) * | 2018-05-17 | 2021-07-22 | Immunome, Inc. | Ch3 domain epitope tags |
GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
CN112423845A (zh) | 2018-07-12 | 2021-02-26 | F星贝塔有限公司 | 结合pd-l1和cd137的抗体分子 |
GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
AU2019301206A1 (en) | 2018-07-12 | 2021-03-04 | F-Star Therapeutics Limited | Antibody molecules that bind CD137 and OX40 |
GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
AR114550A1 (es) | 2018-08-10 | 2020-09-16 | Chugai Pharmaceutical Co Ltd | Moléculas de unión al antígeno anti-cd137 y sus usos |
WO2020056170A1 (en) | 2018-09-12 | 2020-03-19 | Fred Hutchinson Cancer Research Center | Reducing cd33 expression to selectively protect therapeutic cells |
US20220054544A1 (en) * | 2018-09-21 | 2022-02-24 | Harpoon Therapeutics, Inc. | Conditionally active receptors |
JP7425049B2 (ja) | 2018-09-25 | 2024-01-30 | ハープーン セラピューティクス,インク. | Dll3結合タンパク質および使用方法 |
JP2022503959A (ja) | 2018-10-03 | 2022-01-12 | ゼンコア インコーポレイテッド | Il-12ヘテロ二量体fc-融合タンパク質 |
IL282317B2 (en) | 2018-10-17 | 2024-04-01 | Biolinerx Ltd | Treatment of metastatic adenocarcinoma of the pancreas |
EP3930850A1 (de) | 2019-03-01 | 2022-01-05 | Xencor, Inc. | Enpp3 und cd3 bindende heterodimere antikörper |
KR20210149779A (ko) | 2019-04-10 | 2021-12-09 | 추가이 세이야쿠 가부시키가이샤 | Fc 영역 개변 항체의 정제 방법 |
JP2022539248A (ja) | 2019-07-02 | 2022-09-07 | フレッド ハッチンソン キャンサー リサーチ センター | 組換えad35ベクター及び関連遺伝子治療改善 |
CN112898412A (zh) * | 2019-12-03 | 2021-06-04 | 复旦大学 | 一种高稳定性类Fab抗体及其制备方法和应用 |
AU2020403913A1 (en) | 2019-12-18 | 2022-06-09 | F. Hoffmann-La Roche Ag | Bispecific anti-CCL2 antibodies |
PE20230036A1 (es) | 2019-12-23 | 2023-01-10 | Denali Therapeutics Inc | Variantes de progranulina |
AU2019479791A1 (en) | 2019-12-27 | 2022-07-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-CTLA-4 antibody and use thereof |
IL272194A (en) | 2020-01-22 | 2021-07-29 | Yeda Res & Dev | Multi-target antibodies for use in the treatment of diseases |
IL272390A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Cancer treatment methods |
IL272389A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Kits containing antibodies to PD-L1 and their uses in therapy |
TW202144395A (zh) | 2020-02-12 | 2021-12-01 | 日商中外製藥股份有限公司 | 用於癌症之治療的抗cd137抗原結合分子 |
EP4106806A1 (de) | 2020-02-21 | 2022-12-28 | Harpoon Therapeutics, Inc. | Flt3-bindende proteine und verfahren zur verwendung |
CN115397866A (zh) | 2020-03-31 | 2022-11-25 | 中外制药株式会社 | 靶向dll3的多特异性抗原结合分子及其用途 |
BR112022022369A2 (pt) | 2020-05-04 | 2023-03-14 | Immunorizon Ltd | Construtos precursores de anticorpo triespecífico e métodos de uso destes |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
AU2021329378A1 (en) | 2020-08-19 | 2023-03-23 | Xencor, Inc. | Anti-CD28 compositions |
CN116323666A (zh) | 2020-08-21 | 2023-06-23 | 建新公司 | Fgfr3抗体和使用方法 |
WO2022044248A1 (ja) | 2020-08-28 | 2022-03-03 | 中外製薬株式会社 | ヘテロ二量体Fcポリペプチド |
CN117157319A (zh) | 2021-03-09 | 2023-12-01 | Xencor股份有限公司 | 结合cd3和cldn6的异二聚抗体 |
WO2022192586A1 (en) | 2021-03-10 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
TW202309101A (zh) * | 2021-04-19 | 2023-03-01 | 美商健生生物科技公司 | 具有經工程改造之抗體恆定區變體之分子 |
EP4333900A2 (de) | 2021-05-03 | 2024-03-13 | Merck Patent GmbH | Auf her2 abzielende fc-antigenbindende fragment-arzneimittelkonjugate |
AU2022280341A1 (en) | 2021-05-25 | 2024-01-04 | Merck Patent Gmbh | Egfr targeting fc antigen binding fragment-drug conjugates |
WO2022263501A1 (en) | 2021-06-18 | 2022-12-22 | F. Hoffmann-La Roche Ag | Bispecific anti-ccl2 antibodies |
CN117616123A (zh) | 2021-06-25 | 2024-02-27 | 中外制药株式会社 | 抗ctla-4抗体 |
AR126236A1 (es) | 2021-06-25 | 2023-10-04 | Chugai Pharmaceutical Co Ltd | Uso del anticuerpo anti-ctla-4 |
IL286430A (en) | 2021-09-14 | 2023-04-01 | Yeda Res & Dev | Multispecific antibodies for use in the treatment of diseases |
WO2024042105A1 (en) | 2022-08-26 | 2024-02-29 | Merck Patent Gmbh | Cancer treatment comprising an anti-msln/cd137 antibody and a chemotherapeutic |
WO2024042104A1 (en) | 2022-08-26 | 2024-02-29 | Merck Patent Gmbh | Combination cancer treatment comprising an anti-msln/cd137 antibody and pd-1/pd-l1 inhibitor |
Family Cites Families (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0609901A1 (de) | 1984-03-01 | 1994-08-10 | The Board Of Trustees Of The Leland Stanford Junior University | T-Zellenrezeptor, spezifisch für Antigenpolypeptide und verwandte Polynukleotiden |
GB2183661B (en) * | 1985-03-30 | 1989-06-28 | Marc Ballivet | Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique |
US6492107B1 (en) * | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
US5892019A (en) * | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
JP3283041B2 (ja) | 1990-07-13 | 2002-05-20 | 学校法人藤田学園 | 人工抗体 |
WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
DK1471142T3 (da) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimere receptor-biblioteker under anvendelse af fagemider |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
US5395750A (en) * | 1992-02-28 | 1995-03-07 | Hoffmann-La Roche Inc. | Methods for producing proteins which bind to predetermined antigens |
ATE165113T1 (de) | 1992-05-08 | 1998-05-15 | Creative Biomolecules Inc | Mehrwertige chimäre proteine anologe und verfahren zu deren anwendungen |
EP1550729B1 (de) * | 1992-09-25 | 2009-05-27 | Avipep Pty Limited | Zielmoleküle-bindende Polypeptide bestehend aus einer IG-artigen VL Domäne die an eine IG-artige VH Domäne gebunden ist |
US6194166B1 (en) * | 1993-05-24 | 2001-02-27 | Takara Shuzo Co., Ltd. | Gene regulating aureobasidin sensitivity |
US5536814A (en) | 1993-09-27 | 1996-07-16 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
WO1995031483A1 (en) * | 1994-05-13 | 1995-11-23 | Eclagen Limited | Improvements in or relating to peptide delivery |
GB9501079D0 (en) * | 1995-01-19 | 1995-03-08 | Bioinvent Int Ab | Activation of T-cells |
AUPO591797A0 (en) * | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
US6358709B1 (en) * | 1995-12-07 | 2002-03-19 | Diversa Corporation | End selection in directed evolution |
US6361974B1 (en) * | 1995-12-07 | 2002-03-26 | Diversa Corporation | Exonuclease-mediated nucleic acid reassembly in directed evolution |
US6352842B1 (en) * | 1995-12-07 | 2002-03-05 | Diversa Corporation | Exonucease-mediated gene assembly in directed evolution |
CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US6696251B1 (en) | 1996-05-31 | 2004-02-24 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
WO1998039482A1 (en) | 1997-03-07 | 1998-09-11 | Sunol Molecular Corporation | Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor |
US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ,インコーポレイティド | 人工抗体ポリペプチド |
GB9722131D0 (en) * | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
US6477506B1 (en) * | 1998-02-23 | 2002-11-05 | Sony Corporation | Terminal apparatus, information service center, transmitting system, and transmitting method |
EP2261229A3 (de) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glykosylierungs-Engineering von Antikörpern zur Verbesserung der antikörperabhängigen zellvermittelten Zytotoxizität |
US6180343B1 (en) * | 1998-10-08 | 2001-01-30 | Rigel Pharmaceuticals, Inc. | Green fluorescent protein fusions with random peptides |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6376246B1 (en) * | 1999-02-05 | 2002-04-23 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
EP1072010B1 (de) | 1999-01-19 | 2010-04-21 | Maxygen, Inc. | Durch oligonukleotide-vermittelte nukleinsäuren-rekombination |
US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
CA2364997A1 (en) * | 1999-03-05 | 2000-09-08 | Maxygen, Inc. | Encryption of traits using split gene sequences |
US6472147B1 (en) | 1999-05-25 | 2002-10-29 | The Scripps Research Institute | Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries |
DE60028970T2 (de) | 1999-07-02 | 2007-02-15 | Genentech Inc., San Francisco | An her2 bindende peptidverbindungen |
MXPA02005559A (es) | 1999-12-06 | 2004-09-10 | Univ Illinois | Proteinas de tcr de alta afinidad y metodos. |
EP1118661A1 (de) | 2000-01-13 | 2001-07-25 | Het Nederlands Kanker Instituut | T-Zellrezeptor-Bibliotheken |
JP2003274960A (ja) | 2000-02-03 | 2003-09-30 | Japan Science & Technology Corp | 可溶性t細胞受容体タンパク質およびその作成方法 |
WO2001062908A2 (en) | 2000-02-22 | 2001-08-30 | Ahuva Nissim | Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof |
WO2001070947A2 (en) | 2000-03-20 | 2001-09-27 | Maxygen, Inc. | Method for generating recombinant dna molecules in complex mixtures |
EP1278778A2 (de) * | 2000-05-03 | 2003-01-29 | Amgen Inc., | Modifizierte peptide, die eine fc-domäne behalten, als therapeutische agenzien |
AU2001261628A1 (en) | 2000-05-16 | 2001-11-26 | Euroceltique S.A. | Cd28 synthebody for the modulation of immune responses |
WO2001090192A2 (en) * | 2000-05-24 | 2001-11-29 | Imclone Systems Incorporated | Bispecific immunoglobulin-like antigen binding proteins and method of production |
US6406863B1 (en) | 2000-06-23 | 2002-06-18 | Genetastix Corporation | High throughput generation and screening of fully human antibody repertoire in yeast |
WO2002006469A2 (en) | 2000-07-18 | 2002-01-24 | Enchira Biotechnology Corporation | Methods of ligation mediated chimeragenesis utilizing populations of scaffold and donor nucleic acids |
JP2002058479A (ja) | 2000-08-14 | 2002-02-26 | Canon Inc | 構造認識アミノ酸配列の取得方法 |
AU2002213251B2 (en) * | 2000-10-16 | 2007-06-14 | Bristol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
EP1341812A2 (de) * | 2000-11-08 | 2003-09-10 | Incyte Genomics, Inc. | Sekretierte proteine |
GB0029407D0 (en) * | 2000-12-01 | 2001-01-17 | Affitech As | Product |
EP2354149B1 (de) | 2000-12-12 | 2017-08-30 | MedImmune, LLC | Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung |
AU2002246733B2 (en) | 2000-12-19 | 2007-09-20 | Altor Bioscience Corporation | Transgenic animals comprising a humanized immune system |
IL141539A0 (en) | 2001-02-20 | 2002-03-10 | Yeda Res & Dev | Dna molecules and cells transfected therewith |
US20030157561A1 (en) * | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
AU2002256371B2 (en) * | 2001-04-26 | 2008-01-10 | Amgen Mountain View Inc. | Combinatorial libraries of monomer domains |
EP1281757A1 (de) | 2001-07-31 | 2003-02-05 | Direvo Biotech AG | Methode zur Herstellung von Nukleinsäuren mit stochastisch kombinierten Abschnitten von Ausgangsnukleinsäuren |
ES2239246T3 (es) | 2001-08-31 | 2005-09-16 | Avidex Limited | Receptor soluble de celulas t. |
ATE434040T1 (de) | 2001-10-01 | 2009-07-15 | Dyax Corp | Mehrkettige eukaryontische display-vektoren und deren verwendungen |
CA2464271A1 (en) | 2001-10-22 | 2003-05-01 | The Scripps Research Institute | Integrin targeting compounds |
US20040043424A1 (en) * | 2001-11-15 | 2004-03-04 | Baughn Mariah R | Immunoglobulin superfamily proteins |
EP2075256A2 (de) | 2002-01-14 | 2009-07-01 | William Herman | Gezielte Liganden |
US20040063924A1 (en) * | 2002-01-28 | 2004-04-01 | Y Tom Tang | Secreted proteins |
US20030157091A1 (en) * | 2002-02-14 | 2003-08-21 | Dyax Corporation | Multi-functional proteins |
AU2003217580A1 (en) * | 2002-02-19 | 2003-09-09 | Syntherica Corporation | Surrogate antibodies and methods of preparation and use thereof |
US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
CA2478169C (en) | 2002-03-04 | 2013-04-16 | Imclone Systems Incorporated | Human antibodies specific to kdr and uses thereof |
US20040097711A1 (en) * | 2002-03-12 | 2004-05-20 | Henry Yue | Immunoglobulin superfamily proteins |
EP1394251A1 (de) | 2002-08-23 | 2004-03-03 | Direvo Biotech AG | Verfahren zur selektiven Zufallsmutagenese von Polynukleotiden |
EP1549748B1 (de) | 2002-10-09 | 2014-10-01 | Immunocore Ltd. | Einkettige rekombinante t-zell rezeptoren |
EP1900753B1 (de) | 2002-11-08 | 2017-08-09 | Ablynx N.V. | Verfahren zur Verabreichung therapeutischer Polypeptide und Polypeptide dafür |
DK1558643T3 (da) | 2002-11-09 | 2009-09-07 | Immunocore Ltd | Cellereceptorpr sentation |
JP2006523437A (ja) | 2002-12-03 | 2006-10-19 | アヴィデックス リミテッド | レセプター複合体 |
GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
WO2005021595A1 (en) | 2003-08-28 | 2005-03-10 | Euro-Celtique S.A. | Methods of antibody engineering using antibody display rules |
DE602005027309D1 (de) | 2004-01-16 | 2011-05-19 | Regeneron Pharma | Zur aktivierung von rezeptoren fähige fusionspolypeptide |
WO2005092925A2 (en) * | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
JP4773434B2 (ja) | 2004-05-19 | 2011-09-14 | イムノコア リミテッド | 高親和性ny−esot細胞受容体 |
WO2005114215A2 (en) | 2004-05-19 | 2005-12-01 | Avidex Ltd | Method of improving t cell receptors |
GB0411773D0 (en) | 2004-05-26 | 2004-06-30 | Avidex Ltd | Method for the identification of polypeptides which bind to a given peptide mhc complex or cd 1-antigen complex |
ES2521140T3 (es) | 2004-07-22 | 2014-11-12 | Genentech, Inc. | Composición de anticuerpos de HER2 |
DK1797127T3 (en) | 2004-09-24 | 2017-10-02 | Amgen Inc | Modified Fc molecules |
EP1809669A2 (de) | 2004-10-01 | 2007-07-25 | Avidex Ltd | T-zellen-rezeptoren mit einer nicht-nativen disulfidbrücke zwischen den ketten, gebunden an therapeutische mittel |
AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
WO2006054096A2 (en) | 2004-11-18 | 2006-05-26 | Avidex Ltd | Soluble bifunctional proteins |
GB0425732D0 (en) | 2004-11-23 | 2004-12-22 | Avidex Ltd | Gamma-delta t cell receptors |
JP4937138B2 (ja) | 2005-01-05 | 2012-05-23 | エフ−シュタール・ビオテヒノロギシェ・フォルシュングス−ウント・エントヴィックルングスゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 相補性決定領域とは異なる分子の領域に設計された結合性を持つ合成免疫グロブリンドメイン |
GB0503546D0 (en) | 2005-02-21 | 2005-03-30 | Hellenic Pasteur Inst | Antibody |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
CA2648849A1 (en) | 2006-04-14 | 2007-10-25 | Trubion Pharmaceuticals, Inc. | Binding proteins comprising immunoglobulin hinge and fc regions having altered fc effector functions |
AT503889B1 (de) * | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
AT503861B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
EP1975178A1 (de) | 2007-03-30 | 2008-10-01 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Transzytotischer modularer Antikörper |
US7514271B2 (en) | 2007-03-30 | 2009-04-07 | International Business Machines Corporation | Method of forming high density planar magnetic domain wall memory |
WO2009000006A1 (en) | 2007-06-26 | 2008-12-31 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. | Display of binding agents |
WO2009099961A2 (en) | 2008-01-31 | 2009-08-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Engineered antibody constant domain molecules |
EP2113255A1 (de) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Zytotoxisches Immunglobulin |
CA2765478A1 (en) | 2009-07-09 | 2011-01-13 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. | Stabilized immunoglobulin constant domains |
US20120010388A1 (en) | 2010-04-16 | 2012-01-12 | Gottfried Himmler | LeY SPECIFIC BIOTHERAPEUTIC |
EP2407487A1 (de) | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispezifische modulare Antikörper |
US20140087957A1 (en) | 2012-09-25 | 2014-03-27 | Marko Vuskovic | Methods, assays and kits for cancer diagnosis and screening utilizing glycan-binding and glycan epitopes |
GB201317622D0 (en) | 2013-10-04 | 2013-11-20 | Star Biotechnology Ltd F | Cancer biomarkers and uses thereof |
TW201642897A (zh) | 2015-04-08 | 2016-12-16 | F 星生物科技有限公司 | Her2結合劑治療 |
-
2006
- 2006-01-05 JP JP2007549891A patent/JP4937138B2/ja active Active
- 2006-01-05 SI SI200630309T patent/SI1699826T1/sl unknown
- 2006-01-05 AT AT06703578T patent/ATE425186T1/de active
- 2006-01-05 DK DK06703578T patent/DK1699826T3/da active
- 2006-01-05 SI SI200630199T patent/SI1752471T1/sl unknown
- 2006-01-05 EP EP06703578A patent/EP1699826B1/de active Active
- 2006-01-05 EP EP06121439A patent/EP1752471B9/de active Active
- 2006-01-05 PT PT06703578T patent/PT1699826E/pt unknown
- 2006-01-05 EP EP06011173A patent/EP1772465B1/de active Active
- 2006-01-05 NZ NZ555893A patent/NZ555893A/en unknown
- 2006-01-05 PL PL06703578T patent/PL1699826T3/pl unknown
- 2006-01-05 WO PCT/EP2006/050059 patent/WO2006072620A1/en active Application Filing
- 2006-01-05 AT AT06121439T patent/ATE414718T1/de active
- 2006-01-05 RS RSP-2009/0212A patent/RS50785B/sr unknown
- 2006-01-05 KR KR20077014725A patent/KR101404512B1/ko active IP Right Grant
- 2006-01-05 DK DK06121439T patent/DK1752471T3/da active
- 2006-01-05 RS RSP-2009/0267A patent/RS50830B/sr unknown
- 2006-01-05 ES ES06121439T patent/ES2320374T3/es active Active
- 2006-01-05 EA EA200701443A patent/EA018897B1/ru not_active IP Right Cessation
- 2006-01-05 DE DE602006003695T patent/DE602006003695D1/de active Active
- 2006-01-05 PL PL06121439T patent/PL1752471T3/pl unknown
- 2006-01-05 DK DK08168439.1T patent/DK2028193T3/da active
- 2006-01-05 MX MX2007008118A patent/MX2007008118A/es active IP Right Grant
- 2006-01-05 US US11/722,517 patent/US20090298195A1/en not_active Abandoned
- 2006-01-05 PT PT06011173T patent/PT1772465E/pt unknown
- 2006-01-05 DE DE602006005200T patent/DE602006005200D1/de active Active
- 2006-01-05 PL PL06011173T patent/PL1772465T3/pl unknown
- 2006-01-05 RS RSP-2009/0076A patent/RS50752B/sr unknown
- 2006-01-05 DE DE602006005526T patent/DE602006005526D1/de active Active
- 2006-01-05 AU AU2006204459A patent/AU2006204459B2/en active Active
- 2006-01-05 AT AT08168439T patent/ATE548386T1/de active
- 2006-01-05 EP EP08168439A patent/EP2028193B1/de active Active
- 2006-01-05 KR KR1020137018696A patent/KR20130105885A/ko not_active Application Discontinuation
- 2006-01-05 DK DK06011173T patent/DK1772465T3/da active
- 2006-01-05 ES ES08168439T patent/ES2384039T3/es active Active
- 2006-01-05 CN CN201310486561.2A patent/CN103555733A/zh active Pending
- 2006-01-05 SI SI200630280T patent/SI1772465T1/sl unknown
- 2006-01-05 BR BRPI0606399A patent/BRPI0606399A8/pt not_active Application Discontinuation
- 2006-01-05 PT PT08168439T patent/PT2028193E/pt unknown
- 2006-01-05 CN CN200680001831.4A patent/CN101098891B/zh active Active
- 2006-01-05 ES ES06011173T patent/ES2321861T3/es active Active
- 2006-01-05 ES ES06703578T patent/ES2323651T3/es active Active
- 2006-01-05 PT PT06121439T patent/PT1752471E/pt unknown
- 2006-01-05 CA CA2594356A patent/CA2594356C/en active Active
- 2006-01-05 AT AT06011173T patent/ATE423140T1/de active
-
2007
- 2007-06-21 IL IL184103A patent/IL184103A/en active IP Right Grant
-
2009
- 2009-02-12 HR HR20090087T patent/HRP20090087T3/xx unknown
- 2009-02-18 CY CY20091100172T patent/CY1108767T1/el unknown
- 2009-04-20 HR HR20090228T patent/HRP20090228T1/xx unknown
- 2009-05-18 CY CY20091100528T patent/CY1110895T1/el unknown
- 2009-06-02 HR HR20090326T patent/HRP20090326T1/xx unknown
- 2009-06-11 CY CY20091100617T patent/CY1109143T1/el unknown
-
2011
- 2011-05-31 US US13/149,871 patent/US9856311B2/en active Active
- 2011-06-01 US US13/151,207 patent/US20110251375A1/en not_active Abandoned
- 2011-06-01 US US13/151,195 patent/US9045528B2/en active Active
- 2011-12-19 JP JP2011277069A patent/JP5483294B2/ja active Active
-
2013
- 2013-12-17 JP JP2013260218A patent/JP5717833B2/ja active Active
-
2017
- 2017-03-31 US US15/476,029 patent/US10385118B2/en active Active
-
2019
- 2019-04-16 US US16/386,067 patent/US11084868B2/en active Active
- 2019-11-22 US US16/692,220 patent/US11499249B2/en active Active
-
2022
- 2022-10-11 US US17/963,509 patent/US20230340696A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE423140T1 (de) | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften | |
CY1120723T1 (el) | Ανταγωνιστικα αντισωματα il-17 | |
ATE476994T1 (de) | Antikörper gegen gpnmb und ihre verwendungen | |
NO2017032I1 (no) | bezlotoksumab | |
ATE414106T1 (de) | Pegylierte single-domain-antikörper (dab) | |
DK3085783T3 (da) | Bispecifikt antistof som substitution for funktionelle proteiner | |
ATE530195T1 (de) | Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür | |
WO2006113643A3 (en) | High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies | |
CY1110033T1 (el) | Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45 | |
RS53168B (en) | Antibodies and Immunoconjugates and Their Use | |
CY1119890T1 (el) | Θεραπευτικη αγωγη ογκων χρησιμοποιωντας ειδικο αντισωμα αντι-l1 | |
EA200700876A1 (ru) | Агенты, специфически связывающие ангиопоэтин-2 | |
DK1771732T3 (da) | Taxol-immunassay | |
ATE517920T1 (de) | Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1) | |
DE60238987D1 (de) | Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper | |
ATE482980T1 (de) | Antikörper variable region eines monoklonalen antikörpers gegen den humanen tumor nekrose faktor-alpha und dafür kodierendes gen | |
EA202190599A1 (ru) | Анти-tigit антитела |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1772465 Country of ref document: EP |